logo
Book a meeting
MEKanistic Therapeutics

Me Kanistic Therapeutics

Biotechnology, 1015 Glenwood Ave, Minneapolis, Minnesota, 55405, United States, 1-10 Employees

mekanistic.com

  • LinkedIn

phone no Phone Number: 61********

Who is MEKANISTIC THERAPEUTICS

Led by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakth...

Read More

lock icon Get Full Access
map
  • 1015 Glenwood Ave, Minneapolis, Minnesota, 55405, United States Headquarters: 1015 Glenwood Ave, Minneapolis, Minnesota, 55405, United States
  • 2022 Date Founded: 2022
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from MEKANISTIC THERAPEUTICS

MEKanistic Therapeutics Org Chart and Mapping

Employees
Christopher Whitehead

Christopher Whitehead

Chief Operations Officer

See Full Org Chart arrow
email-formate-icon
View Email Formats for MEKanistic Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding MEKanistic Therapeutics

Answer: MEKanistic Therapeutics's headquarters are located at 1015 Glenwood Ave, Minneapolis, Minnesota, 55405, United States

Answer: MEKanistic Therapeutics's phone number is 61********

Answer: MEKanistic Therapeutics's official website is https://mekanistic.com

Answer: MEKanistic Therapeutics's revenue is Under $1 Million

Answer: MEKanistic Therapeutics's SIC: 2834

Answer: MEKanistic Therapeutics's NAICS: 325412

Answer: MEKanistic Therapeutics has 1-10 employees

Answer: MEKanistic Therapeutics is in Biotechnology

Answer: MEKanistic Therapeutics contact info: Phone number: 61******** Website: https://mekanistic.com

Answer: Led by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window by inhibiting compensatory resistance pathways at the same time, avoiding inherent toxicity challenges of multi-compound treatments.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access